| Today’s Big NewsOct 30, 2024 |
| By Nick Paul Taylor GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a preclinical 30-plus valent shot. A spokesperson for GSK said “increased competition” drove the decision. |
|
|
|
By Nick Paul Taylor Eli Lilly has dropped the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC-806 to the curb as part of a third-quarter cull that also affected the PD-1 autoimmune prospect peresolimab. |
By Gabrielle Masson Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. |
Sponsored by Questex Fierce Biotech sits down with digital marketing leaders to discuss this year's most innovative topics at Fierce Biotech Summit and New Product Planning |
|
| 45 markers for cytokine signaling/inflammationTrust RBM for Olink, Luminex & Simoa immunoassays
|
|
By Darren Incorvaia Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go after tough targets in Alzheimer’s and rare neurological and immunological diseases, the company announced in an Oct. 29 release. |
Sponsored by Turbine.Ai Join us on the latest Top Line podcast as we dive into how Turbine Simulated Cell Technologies is reshaping drug development. Discover their innovative approaches to combatting biases in data, leading to more effective cancer treatments. Tune in now! |
By Nick Paul Taylor Not much went right for Spero Therapeutics’ SPR720 in its phase 2a trial. An interim analysis revealed a double blow to the oral antibiotic candidate, which both failed to beat placebo and showed signs of liver toxicity. Spero responded by laying off 39% of its employees to extend its cash runway to mid-2026. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Darren Incorvaia As its lead gene therapy flows toward the clinic, Purespring Therapeutics is uncorking new preclinical data showing the candidate reduced kidney scarring and fibrosis in mice and safely delivered a gene to pig kidneys. |
By Eric Sagonowsky In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial medicine and giving up hopes for a pair of pipeline prospects. |
By Heather Landi Walgreens is conducting another round of layoffs as the drugstore giant looks to significantly cut costs and turnaround its financial performance. |
By Kevin Dunleavy Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of analyst expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation that skyrocketing demand for the blood sugar modulating treatments has maxed out. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Medtech's Conor Hale dives into EY's 18th annual Pulse of the MedTech Industry report and chats with EY's John Babbitt about the team's findings and the pace of M&A, venture capital funding and recent IPOs. |
|
|---|
|
|
|
Wednesday, November 6, 2024 | 1pm ET / 10am PT Generative AI models help scientists better understand proteins, small molecules, DNA, biomedical text, and more. But building, training, and deploying these models can be complex. Join us to discuss the benefits of moving to the cloud to accelerate drug discovery pipelines, and why using customized AI models can help you get to market faster. Register now.
|
|
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
| eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
